THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Research and Practice in Thrombosis and Haemostasis, published by Elsevier, is a prominent open-access journal dedicated to advancing the field of hematology through high-quality research and clinical practice. Since its inception in 2017, this journal has established itself as a vital resource for researchers, healthcare professionals, and students interested in thrombosis and hemorrhage management, showcasing original research, reviews, and clinical studies. The journal’s commitment to accessible knowledge is reflected in its open-access model, allowing researchers worldwide to share their findings without financial barriers. With an impressive 2023 Scopus rank of #42 out of 137 in the hematology category and a respectable Q2 classification, it provides an authoritative platform for innovative ideas and cutting-edge developments in the field. As the journal continues to grow in stature, it aims to foster collaboration and knowledge exchange amongst professionals dedicated to improving patient outcomes in thrombosis and hemostasis.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, published by Springer in the Netherlands, serves as a vital platform for research in the fields of Cardiology and Cardiovascular Medicine and Hematology. With an impressive impact factor, this journal ranks in the Q2 category for both fields according to the latest metrics, evidencing its significant influence and contribution to ongoing scholarly discourse. Spanning over three decades from 1994 to 2024, the journal provides an essential source for innovative studies, clinical practices, and comprehensive reviews related to thrombosis and thrombolysis. Researchers, clinicians, and students alike will find valuable insights and cutting-edge knowledge that address the complexities of blood coagulation and its implications in cardiovascular health. The journal is indexed in Scopus, with commendable rankings, further establishing its reputation in the academic community.

HEMOGLOBIN, a prominent journal published by Taylor & Francis Ltd, serves as a vital resource in the fields of Biochemistry, Clinical Biochemistry, Genetics, and Hematology. Established in 1976, the journal provides a platform for innovative research and review articles that explore the complexities of hemoglobin pathology and related disorders, making significant contributions to our understanding of hematological diseases. With an ISSN of 0363-0269 and an E-ISSN of 1532-432X, HEMOGLOBIN has garnered attention within the academic community, reflected in its category quartiles for 2023, which rank it in the Q3 and Q4 levels across relevant medical and biochemistry categories. Although it operates on a subscription basis rather than as an open-access journal, it remains influential, providing critical insights to researchers, professionals, and students aiming to address the current challenges in blood research and related fields. The journal not only emphasizes high-quality scientific analyses but also seeks to foster collaboration and dialogue among academia and clinical practitioners, ultimately advancing the frontier of knowledge in hemoglobin and hematological research.

BLOOD COAGULATION & FIBRINOLYSIS, a distinguished journal in the field of hematology, is published by Lippincott Williams & Wilkins, a reputable name in academic publishing. Since its inception in 1990, this journal has been committed to advancing the understanding of blood coagulation and fibrinolysis, focusing on the molecular mechanisms, clinical implications, and therapeutic aspects of these critical processes. With an impact factor reflecting its significance within the academic community, currently ranking Q3 in both Hematology and Miscellaneous Medicine for 2023, this journal serves as a pivotal platform for researchers and professionals alike. By providing access to cutting-edge research and reviews, BLOOD COAGULATION & FIBRINOLYSIS endeavors to foster collaboration and innovation in the treatment of coagulation disorders. Interested readers can explore ongoing contributions to the field through subscriptions and institutional access options.

Thrombosis Journal is a pioneering open-access publication offering critical insights into the field of hematology, contributing significantly to the understanding of thrombotic diseases. Published by BMC since its inception in 2003, this journal stands out with its commitment to accessibility and dissemination of research, ensuring that valuable findings are readily available to the global scientific community. With an impressive Q2 ranking in the Hematology category as of 2023, the journal boasts a notable presence in the Scopus rankings, positioned at Rank #73/137 in its field. Researchers, healthcare professionals, and students can benefit from a rich array of articles that encompass clinical studies, reviews, and innovative methodologies, all aimed at advancing knowledge and fostering collaboration in the field. The journal is headquartered in the United Kingdom, and its open-access model has enabled a diversity of perspectives and research innovations to flourish, solidifying Thrombosis Journal as an essential resource for those dedicated to combating thrombotic disorders.

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.